7-chloro-4-(4-diethylamino-1-methyl-butylamino)-quinolin-2-ol | 7597-00-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 7-chloro-4-(4-diethylamino-1-methyl-butylamino)-quinolin-2-ol
• 英文别名: 7-Chlor-4-(4-diaethylamino-1-methyl-butylamino)-chinolin-2-ol；7-chloro-4-[5-(diethylamino)pentan-2-ylamino]-1H-quinolin-2-one
• CAS: 7597-00-4
• 化学式: C₁₈H₂₆ClN₃O
• 分子量: 335.877
• InChiKey: TXUZHSKEYRFSCA-UHFFFAOYSA-N

物化性质

• 熔点：
  223.1-225 °C
• 沸点：
  498.8±45.0 °C(Predicted)
• 密度：
  1.15±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  23
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  44.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-氨基-5-二乙基氨基戊烷 、 4,7-dichloroquinolin-2(1H)-one 生成 7-chloro-4-(4-diethylamino-1-methyl-butylamino)-quinolin-2-ol
  参考文献：
  名称：

  合成抗疟药；某些4-氨基喹啉的制备。

  摘要：

  DOI：

  10.1021/ja01211a021

文献信息

• PHARMACEUTICAL COMPOSITION COMPRISING AMODIAQUINE AND ANTI-DIABETES DRUG AS EFFECTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF DIABETES
  申请人：Novmetapharma Co., Ltd.

  公开号：EP3498279A1

  公开（公告）日：2019-06-19

  The present invention relates to a pharmaceutical composition for preventing or treating diabetes, and controlling a side effect from peroxisome proliferator-activated receptor-gamma (PPAR-gamma) activation, wherein the pharmaceutical composition comprises (a) an amodiaquine compound or a pharmaceutically acceptable salt thereof and (b) an antidiabetic drug as active ingredients. Specifically, the composition prevents or treats simultaneously one or more selected from the group consisting of type 2 diabetes reactive to PPAR-gamma activation, and obesity, dyslipidemia, cardiovascular diseases, and fatty cirrhosis reactive to peroxisome proliferator-activated receptor-alpha (PPAR- alpha) activation.

  本发明涉及一种用于预防或治疗糖尿病以及控制过氧化物酶体增殖物激活受体-γ（PPAR-γ）激活产生的副作用的药物组合物，其中药物组合物包括(a)作为活性成分的阿莫地喹化合物或其药学上可接受的盐和(b)抗糖尿病药物。具体地说，该组合物可同时预防或治疗选自以下组别的一种或多种疾病：对 PPAR-gamma 激活有反应的 2 型糖尿病，以及对过氧化物酶体增殖激活受体-α（PPAR-α）激活有反应的肥胖症、血脂异常、心血管疾病和脂肪性肝硬化。
• Pharmaceutical composition comprising amodiaquine and anti-diabetes drug as effective ingredient for prevention or treatment of diabetes
  申请人：NOVMETAPHARMA CO., LTD.

  公开号：US10792280B2

  公开（公告）日：2020-10-06

  The present invention relates to a pharmaceutical composition for preventing or treating diabetes, and controlling a side effect from peroxisome proliferator-activated receptor-gamma (PPAR-gamma) activation, wherein the pharmaceutical composition comprises (a) an amodiaquine compound or a pharmaceutically acceptable salt thereof and (b) an antidiabetic drug as active ingredients. Specifically, the composition prevents or treats simultaneously one or more selected from the group consisting of type 2 diabetes reactive to PPAR-gamma activation, and obesity, dyslipidemia, cardiovascular diseases, and fatty cirrhosis reactive to peroxisome proliferator-activated receptor-alpha (PPAR-alpha) activation.

  本发明涉及一种用于预防或治疗糖尿病以及控制过氧化物酶体增殖物激活受体-γ（PPAR-γ）激活产生的副作用的药物组合物，其中药物组合物包括(a)作为活性成分的阿莫地喹化合物或其药学上可接受的盐和(b)抗糖尿病药物。具体地说，该组合物可同时预防或治疗选自以下组别的一种或多种疾病：对 PPAR-gamma 激活有反应的 2 型糖尿病，以及对过氧化物酶体增殖物激活受体-α（PPAR-α）激活有反应的肥胖症、血脂异常、心血管疾病和脂肪性肝硬化。
• [EN] ANTIVIRAL AGENTS FOR TREATING ZIKA AND DENGUE VIRUS INFECTIONS<br/>[FR] AGENTS ANTIVIRAUX POUR LE TRAITEMENT D'INFECTIONS PAR LE LE VIRUS ZIKA ET DE LA DENGUE
  申请人：UNIV EMORY

  公开号：WO2017165489A1

  公开（公告）日：2017-09-28

  The present invention is directed to compounds, compositions and methods for treating or preventing Zika virus. The compounds include pyrimidine and purine nucleosides and prodrugs thereof, including certain N4-hydroxycytidine nucleoside derivatives, sulfasalazine, and various entry inhibitors.
• Synthetic Antimalarials. The Preparation of Certain 4-Aminoquinolines¹
  作者：Nathan L. Drake、Hugh J. Creech、John A. Garman、Stuart T. Haywood、Richard M. Peck、John O. van Hook、Edward Walton

  DOI：10.1021/ja01211a021

  日期：1946.7